Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dinutuximab

(din-yoo-TUK-sih-mab)
A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has gotten better with other anticancer treatment. Dinutuximab binds to a substance called GD2, which is found on some types of cancer cells. Dinutuximab may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Ch14.18, MOAB Ch14.18, monoclonal antibody Ch14.18, and Unituxin.
Search NCI's Dictionary of Cancer Terms